Wanbury Limited has announced key board decisions regarding the re-appointment of its Independent Director and scheduling of an Extraordinary General Meeting. The pharmaceutical company's board meeting held on December 10, 2025, addressed important governance matters requiring shareholder approval.

Board Approves Director Re-appointment

The Board of Directors approved the re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director. His current tenure is set to end on January 7, 2026, and the proposed re-appointment will be effective from January 8, 2026, to January 7, 2027.

Mr. Gursahani has confirmed that he continues to meet the criteria of independence under the provisions of the Companies Act, 2013, and the SEBI Listing Regulations.

Extraordinary General Meeting Scheduled

The board has approved the issuance of notice for convening an Extraordinary General Meeting (EGM) of shareholders. The meeting is scheduled for Monday, January 5, 2026, to seek necessary approval from shareholders for the re-appointment through a special resolution.

Director Profile and Experience

Mr. Manojkumar Khubchand Gursahani brings over 30 years of professional experience to the board. He is a distinguished thought leader holding a graduate degree from Mumbai University and serves as a TED speaker, global strategist, and author of "The Human Connect."

His professional accomplishments include:

• Co-founder of Vera Healthcare Technologies, an AI-driven platform for early detection of ocular diseases
• Executive Director at the Global Chamber
• Mumbai Chair for the Las Vegas Chamber of Commerce
• Managing Trustee of the Indian Relief Foundation
• Advisor to Lion Tarachand Bapa Hospital
• Immediate Past President of the Rotary Club of Queens Necklace, Mumbai

Compliance and Independence

The company has confirmed that Mr. Gursahani is not related to any of the directors of the company and is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. This ensures compliance with regulatory requirements for independent directors.

Meeting Details

The board meeting commenced at 4:30 PM and concluded at 5:15 PM on December 10, 2025. The company has informed both BSE Limited and National Stock Exchange of India about these decisions in accordance with Regulation 30 of the SEBI Listing Regulations.

Wanbury Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of FY26, showcasing a robust performance and strategic corporate actions.

Financial Highlights

Wanbury reported significant growth in its quarterly results:

The company achieved an EBITDA of ₹26.00 crore (16.20% margin) in Q2 FY26 compared to ₹21.60 crore (13.30% margin) in Q2 FY25, marking 20% growth. This performance indicates a strong financial position and operational efficiency, driven by enhanced product yields and procurement efficiencies.

Wanbury's PAT surged 89% to ₹15.20 crore from ₹8.00 crore year-over-year, demonstrating significant bottom-line improvement.

Business Segment Performance

• The formulations business turned EBITDA positive
• The API business maintained strong performance

Strategic Initiatives

The company highlighted successful digital transformation efforts and expressed commitment to sustainable growth through new product launches. Notably, Wanbury successfully launched a new iron supplement brand called C-red.

Employee Stock Option Plan

Wanbury's Board approved the allotment of 15,000 equity shares under its Employee Stock Option Plan 2016 (WANBURY ESOP 2016). These shares, with a face value of ₹10 each, were issued at par to an eligible employee who exercised vested options.

Impact on Share Capital

Following this allotment, Wanbury's paid-up share capital has increased to ₹34,89,19,980, divided into 3,48,91,998 fully paid-up equity shares of ₹10 each. This represents an increase from the previous share capital of ₹34,87,69,980.

Corporate Actions

During the quarter, the company also allotted 20,00,000 equity shares upon the exercise of conversion options attached to warrants. This resulted in an increase of ₹200.00 lakhs in the paid-up share capital and ₹2,200.00 lakhs in the Securities Premium account.

Management Commentary

The management expressed satisfaction with the company's performance, highlighting the success of their business model and the dedication of their team. The allotment of employee stock options underscores their commitment to aligning the workforce with the company's long-term success.

Future Outlook

Wanbury continues to focus on its core pharmaceutical segment, leveraging its US FDA-approved manufacturing facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra) to drive growth. The company's commitment to sustainable growth through new product launches, as evidenced by the introduction of C-red, suggests a positive outlook for future quarters.